Humanized bone facilitates prostate cancer metastasis and recapitulates therapeutic effects of zoledronic acid in vivo

Abstract

Advanced prostate cancer (PCa) is known for its high prevalence to metastasize to bone, at which point it is considered incurable. Despite significant effort, there is no animal model capable of recapitulating the complexity of PCa bone metastasis. The humanized mouse model for PCa bone metastasis used in this study aims to provide a platform for the assessment of new drugs by recapitulating the human–human cell interactions relevant for disease development and progression. The humanized tissue-engineered bone construct (hTEBC) was created within NOD-scid IL2rg^null (NSG) mice and was used for the study of experimental PC3-Luc bone metastases. It was confirmed that PC3-Luc cells preferentially grew in the hTEBC compared with murine bone. The translational potential of the humanized mouse model for PCa bone metastasis was evaluated with two clinically approved osteoprotective therapies, the non-species-specific bisphosphonate zoledronic acid (ZA) or the human-specific antibody Denosumab, both targeting Receptor Activator of Nuclear Factor Kappa-Β Ligand. ZA, but not Denosumab, significantly decreased metastases in hTEBCs, but not murine femora. These results highlight the importance of humanized models for the preclinical research on PCa bone metastasis and indicate the potential of the bioengineered mouse model to closely mimic the metastatic cascade of PCa cells to human bone. Eventually, it will enable the development of new effective antimetastatic treatments.

References

[1] Bray F et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin., 2018, 68:394-424

[2] Saad F et al. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. JNCI J. Natl Cancer Inst., 2004, 96:879-882

[3] Mundy GR. Metastasis to bone: causes, consequences and therapeutic opportunities. Nat. Rev. Cancer, 2002, 2:584-593

[4] Sturge J, Caley MP, Waxman J. Bone metastasis in prostate cancer: emerging therapeutic strategies. Nat. Rev. Clin. Oncol., 2011, 8:357-368

[5] Deng X et al. Recent advances in bone-targeted therapies of metastatic prostate cancer. Cancer Treat. Rev., 2014, 40:730-738

[6] Tannock IF et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N. Engl. J. Med., 2004, 351:1502-1512

[7] Miller KD et al. Cancer treatment and survivorship statistics, 2016. CA Cancer J. Clin., 2016, 66:271-289

[8] Shiozawa Y et al. Human prostate cancer metastases target the hematopoietic stem cell niche to establish footholds in mouse bone marrow. J. Clin. Invest., 2011, 121:1298-1312

[9] Seruga B, Ocana A, Tannock IF. Drug resistance in metastatic castration-resistant prostate cancer. Nat. Rev. Clin. Oncol., 2011, 8:12-23

[10] Oades GM, Coxon J, Colston KW. The potential role of bisphosphonates in prostate cancer. Prostate Cancer Prostatic Dis., 2002, 5:264

[11] Steeg PS. Targeting metastasis. Nat. Rev. Cancer, 2016, 16:201

[12] Chirgwin JM, Guise TA. Skeletal metastases: decreasing tumor burden by targeting the bone microenvironment. J. Cell. Biochem., 2007, 102:1333-1342

[13] Cleeland CS et al. Pain outcomes in patients with advanced breast cancer and bone metastases. Cancer, 2013, 119:832-838

[14] Flanagan AM, Chambers TJ. Inhibition of bone resorption by bisphosphonates: interactions between bisphosphonates, osteoclasts, and bone. Calcif. Tissue Int., 1991, 49:407-415

[15] Ibrahim A et al. Approval summary for zoledronic aacid for treatment of multiple myeloma and cancer bone metastases. Clin. Cancer Res., 2003, 9:2394-2399

[16] Green J, Lipton A. Anticancer properties of zoledronic acid. Cancer Invest., 2010, 28:944-957

[17] Qiao H et al. Targeting osteocytes to attenuate early breast cancer bone metastasis by theranostic upconversion nanoparticles with responsive plumbagin release. ACS Nano, 2017, 11:7259-7273

[18] Zekri J, Mansour M, Karim SM. The anti-tumour effects of zoledronic acid. J. Bone Oncol., 2014, 3:25-35

[19] Rizzoli R. Zoledronic acid for the treatment and prevention of primary and secondary osteoporosis. Ther. Adv. Musculoskelet. Dis., 2010, 2:3-16

[20] Hanley DA, Adachi JD, Bell A, Brown V. Denosumab: mechanism of action and clinical outcomes. Int. J. Clin. Pract., 2012, 66:1139-1146

[21] Ortiz, A. & Lin, S.-H. Osteolytic and osteoblastic bone metastases: two extremes of the same spectrum? Recent Results Cancer Res. Fortschritte Krebsforsch. Progres Dans Rech. Sur Cancer 192, 225–233 (2012).

[22] Hegemann M, Bedke J, Stenzl A, Todenhöfer T. Denosumab treatment in the management of patients with advanced prostate cancer: clinical evidence and experience. Ther. Adv. Urol., 2017, 9:81-88

[23] Fizazi K et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet, 2011, 377:813-822

[24] Scher HI. Prostate carcinoma. Cancer, 2003, 97:758-771

[25] Simmons JK, Elshafae SM, Keller ET, McCauley LK, Rosol TJ. Review of animal models of prostate cancer bone metastasis. Vet. Sci., 2014, 1:16-39

[26] Kostenuik PJ et al. Denosumab, a fully human monoclonal antibody to RANKL, inhibits bone resorption and increases BMD in knock-in mice that express chimeric (murine/human) RANKL. J. Bone Miner. Res., 2009, 24:182-195

[27] Little DG. Humanizing a mouse gene for human therapeutics: lessons from denosumab. J. Bone Miner. Res., 2009, 24:179-181

[28] Holzapfel BM et al. Species-specific homing mechanisms of human prostate cancer metastasis in tissue engineered bone. Biomaterials, 2014, 35:4108-4115

[29] Wagner F et al. A validated preclinical animal model for primary bone tumor research. J. Bone Jt. Surg. Am., 2016, 98:916-925

[30] Thibaudeau L et al. Mimicking breast cancer-induced bone metastasis in vivo: current transplantation models and advanced humanized strategies. Cancer Metastasis Rev., 2014, 33:721-735

[31] Thibaudeau L, Holzapfel BM, Hutmacher DW. Humanized mice models for primary bone tumor and bone metastasis research. Cell Cycle, 2015, 14:2191-2192

[32] Martine LC et al. Engineering a humanized bone organ model in mice to study bone metastases. Nat. Protoc., 2017, 12:639-663

[33] Tukey, J. W. Exploratory Data Analysis (Pearson, Reading, Massachusetts, USA, 1977).

[34] Chu K et al. Cadherin-11 promotes the metastasis of prostate cancer cells to bone. Mol. Cancer Res., 2008, 6:1259-1267

[35] Baba, A. I. & Câtoi, C. Tumor Cell Morphology (The Publishing House of the Romanian Academy, Bucharest, Romania, 2007).

[36] Paget S. The distribution of secondary growths in cancer of the breast. Lancet, 1889, 133:571-573

[37] Holzapfel BM et al. Humanised xenograft models of bone metastasis revisited: novel insights into species-specific mechanisms of cancer cell osteotropism. Cancer Metastasis Rev., 2013, 32:129-145

[38] Bhowmick NA, Neilson EG, Moses HL. Stromal fibroblasts in cancer initiation and progression. Nature, 2004, 432:332-337

[39] Turner CJ, Edwards CM. The role of the microenvironment in prostate cancer-associated bone disease. Curr. Osteoporos. Rep., 2016, 14:170-177

[40] Barcellos-Hoff MH, Lyden D, Wang TC. The evolution of the cancer niche during multistage carcinogenesis. Nat. Rev. Cancer, 2013, 13:511-518

[41] McGovern JA et al. Humanization of the prostate microenvironment reduces homing of PC3 prostate cancer cells to human tissue-engineered bone. Cancers, 2018, 10:438

[42] Chen Q, Khoury M, Chen J. Expression of human cytokines dramatically improves reconstitution of specific human-blood lineage cells in humanized mice. Proc. Natl Acad. Sci. USA., 2009, 106:21783-21788

[43] Reinisch A, Hernandez DC, Schallmoser K, Majeti R. Generation and use of a humanized bone-marrow-ossicle niche for hematopoietic xenotransplantation into mice. Nat. Protoc., 2017, 12:2169-2188

[44] Hesami P et al. A humanized tissue-engineered in vivo model to dissect interactions between human prostate cancer cells and human bone. Clin. Exp. Metastasis, 2014, 31:435-446

[45] Tannehill-Gregg SH, Levine AL, Nadella MVP, Iguchi H, Rosol TJ. The effect of zoledronic acid and osteoprotegerin on growth of human lung cancer in the tibias of nude mice. Clin. Exp. Metastasis, 2006, 23:19-31

[46] O’Neill K, Lyons SK, Gallagher WM, Curran KM, Byrne AT. Bioluminescent imaging: a critical tool in pre-clinical oncology research. J. Pathol., 2010, 220:317-327

[47] Shafiee A et al. Immune system augmentation via humanization using stem/progenitor cells and bioengineering in a breast cancer model study. Int. J. Cancer, 2018, 143:1470-1482

[48] Green JR. Preclinical profile of zoledronic acid in prostate cancer models. Eur. Urol. Suppl., 2004, 3:16-24

[49] Thudi NK et al. Zoledronic acid decreased osteolysis but not bone metastasis in a nude mouse model of canine prostate cancer with mixed bone lesions. Prostate, 2008, 68:1116-1125

[50] Joyce, M. H. et al. Phenotypic basis for matrix stiffness-dependent chemoresistance of breast cancer cells to doxorubicin. Front. Oncol. 8, 337 (2018).

[51] Horas, K. et al. Loss of the vitamin D receptor in human breast cancer cells promotes epithelial to mesenchymal cell transition and skeletal colonization. J. Bone Miner. Res. (2019). https://doi.org/10.1002/jbmr.3744.

[52] Havens AM et al. An in vivo mouse model for human prostate cancer metastasis. Neoplasia, 2008, 10:371-379

[53] Jo Y et al. Chemoresistance of cancer cells: requirements of tumor microenvironment-mimicking in vitro models in anti-cancer drug development. Theranostics, 2018, 8:5259-5275

[54] Ganguly, S. S., Li, X. & Miranti, C. K. The host microenvironment influences prostate cancer invasion, systemic spread, bone colonization, and osteoblastic metastasis. Front. Oncol. 4, 364 (2014).

[55] Paindelli C, Navone N, Logothetis CJ, Friedl P, Dondossola E. Engineered bone for probing organotypic growth and therapy response of prostate cancer tumoroids in vitro. Biomaterials, 2019, 197:296-304

[56] Aguado, B. A., Bushnell, G. G., Rao, S. S., Jeruss, J. S. & Shea, L. D. Engineering the pre-metastatic niche. Nat. Biomed. Eng. 1, 0077 (2017).

[57] Landgraf M, McGovern JA, Friedl P, Hutmacher DW. Rational design of mouse models for cancer research. Trends Biotechnol., 2018, 36:242-251

[58] Brown TD et al. Design and fabrication of tubular scaffolds via direct writing in a melt electrospinning mode. Biointerphases, 2012, 7:1-16

[59] Vaquette C, Ivanovski S, Hamlet SM, Hutmacher DW. Effect of culture conditions and calcium phosphate coating on ectopic bone formation. Biomaterials, 2013, 34:5538-5551

[60] Reichert JC et al. Mineralized human primary osteoblast matrices as a model system to analyse interactions of prostate cancer cells with the bone microenvironment. Biomaterials, 2010, 31:7928-7936

[61] Loessner D et al. Functionalization, preparation and use of cell-laden gelatin methacryloyl–based hydrogels as modular tissue culture platforms. Nat. Protoc., 2016, 11:727

[62] Hayman AR. Tartrate-resistant acid phosphatase (TRAP) and the osteoclast/immune cell dichotomy. Autoimmunity, 2008, 41:218-223

[63] Norman, G. R. & Streiner, D. L. Pdq Statistics (PDQ Series) 3rd edn (PMPH USA, 2003).

[64] Thakur SS et al. The use of automated Ki67 analysis to predict Oncotype DX risk-of-recurrence categories in early-stage breast cancer. PloS ONE, 2018, 13